2026 Q2 - tulosraportti
46 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·11 min sitten40 million people globally have this disorder - so not uninteresting ! A Swedish study with almost 15,000 people with bipolar disorder has investigated the use of GLP-1 medication over 15 years. * People who used semaglutide – the active substance in, among others, Ozempic and Wegovy – had a 21 % lower risk of psychiatric hospitalization than during periods when they did not use GLP-1 medication. * Researchers believe that GLP-1 signaling may possibly affect processes in the brain, including inflammation and cellular stress, which can be significant for bipolar disorder. https://www.dagens.dk/sundhed/ozempic-og-wegovy-forbindes-med-overraskende-fordel-det-handler-ikke-om-vaegttab?utm_source=facebook&utm_medium=social&utm_campaign=dagens_nyheder&utm_id=59838cf54e6f&fbclid=IwdGRjcAUcn6twZG9mBWZkaWQWUOzzpSeZt5e3Bg85EmyUbl5N4I-grmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7mWR1V7cxiSmayfEtbVjscyH8Q0Us48yqZ9aSjnCylJrhGlmYWkLmznOr_RA_aem_oo9FuD3LW3L_e5gSSFtzPQ
·17 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
·18 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicineNovo Nordisk is my largest position and constitutes approximately 12 % of my three portfolios. For me, the stock functions both as a long-term investment and as a flexible liquidity reserve. My Novo Nordisk ordinary shares are potentially for sale when the price is right at some point. The extra Novo Nordisk shares, which I have bought in addition, I use more actively as my "bank". The strategy is that I buy Novo Nordisk shares when the price is very low. When I need money for another stock, I can sell part of the Novo Nordisk holding again. In that way, the holding functions as a bank account with free possibility to deposit money and withdraw again, but with the possibility of profit. Sometimes I sell with a profit compared to my average acquisition cost, other times with a profit compared to last week's purchase price. In addition, Novo Nordisk provides ordinary dividend twice a year at the present time, in addition to the possible gain on the price by buying and selling on a weekly basis. And in the long term, the potential is greater And I'm happy to wait
·20 t sittenis not worth the risk for me, glad that I didn't buy in.
·22 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.
I generally agree, but also think the case is more uncertain than it was in 2024. CagriSema has disappointed relative to expectations, and Novo must now prove that zenagamtide and the rest of the pipeline can actually take over as the next growth engine. The market is growing, but that doesn't mean Novo automatically will. That's exactly what CMD needs to convince investors of.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
46 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 min sitten40 million people globally have this disorder - so not uninteresting ! A Swedish study with almost 15,000 people with bipolar disorder has investigated the use of GLP-1 medication over 15 years. * People who used semaglutide – the active substance in, among others, Ozempic and Wegovy – had a 21 % lower risk of psychiatric hospitalization than during periods when they did not use GLP-1 medication. * Researchers believe that GLP-1 signaling may possibly affect processes in the brain, including inflammation and cellular stress, which can be significant for bipolar disorder. https://www.dagens.dk/sundhed/ozempic-og-wegovy-forbindes-med-overraskende-fordel-det-handler-ikke-om-vaegttab?utm_source=facebook&utm_medium=social&utm_campaign=dagens_nyheder&utm_id=59838cf54e6f&fbclid=IwdGRjcAUcn6twZG9mBWZkaWQWUOzzpSeZt5e3Bg85EmyUbl5N4I-grmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7mWR1V7cxiSmayfEtbVjscyH8Q0Us48yqZ9aSjnCylJrhGlmYWkLmznOr_RA_aem_oo9FuD3LW3L_e5gSSFtzPQ
- ·17 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
- ·18 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicineNovo Nordisk is my largest position and constitutes approximately 12 % of my three portfolios. For me, the stock functions both as a long-term investment and as a flexible liquidity reserve. My Novo Nordisk ordinary shares are potentially for sale when the price is right at some point. The extra Novo Nordisk shares, which I have bought in addition, I use more actively as my "bank". The strategy is that I buy Novo Nordisk shares when the price is very low. When I need money for another stock, I can sell part of the Novo Nordisk holding again. In that way, the holding functions as a bank account with free possibility to deposit money and withdraw again, but with the possibility of profit. Sometimes I sell with a profit compared to my average acquisition cost, other times with a profit compared to last week's purchase price. In addition, Novo Nordisk provides ordinary dividend twice a year at the present time, in addition to the possible gain on the price by buying and selling on a weekly basis. And in the long term, the potential is greater And I'm happy to wait
- ·20 t sittenis not worth the risk for me, glad that I didn't buy in.
- ·22 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.I generally agree, but also think the case is more uncertain than it was in 2024. CagriSema has disappointed relative to expectations, and Novo must now prove that zenagamtide and the rest of the pipeline can actually take over as the next growth engine. The market is growing, but that doesn't mean Novo automatically will. That's exactly what CMD needs to convince investors of.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
46 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 min sitten40 million people globally have this disorder - so not uninteresting ! A Swedish study with almost 15,000 people with bipolar disorder has investigated the use of GLP-1 medication over 15 years. * People who used semaglutide – the active substance in, among others, Ozempic and Wegovy – had a 21 % lower risk of psychiatric hospitalization than during periods when they did not use GLP-1 medication. * Researchers believe that GLP-1 signaling may possibly affect processes in the brain, including inflammation and cellular stress, which can be significant for bipolar disorder. https://www.dagens.dk/sundhed/ozempic-og-wegovy-forbindes-med-overraskende-fordel-det-handler-ikke-om-vaegttab?utm_source=facebook&utm_medium=social&utm_campaign=dagens_nyheder&utm_id=59838cf54e6f&fbclid=IwdGRjcAUcn6twZG9mBWZkaWQWUOzzpSeZt5e3Bg85EmyUbl5N4I-grmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7mWR1V7cxiSmayfEtbVjscyH8Q0Us48yqZ9aSjnCylJrhGlmYWkLmznOr_RA_aem_oo9FuD3LW3L_e5gSSFtzPQ
- ·17 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
- ·18 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicineNovo Nordisk is my largest position and constitutes approximately 12 % of my three portfolios. For me, the stock functions both as a long-term investment and as a flexible liquidity reserve. My Novo Nordisk ordinary shares are potentially for sale when the price is right at some point. The extra Novo Nordisk shares, which I have bought in addition, I use more actively as my "bank". The strategy is that I buy Novo Nordisk shares when the price is very low. When I need money for another stock, I can sell part of the Novo Nordisk holding again. In that way, the holding functions as a bank account with free possibility to deposit money and withdraw again, but with the possibility of profit. Sometimes I sell with a profit compared to my average acquisition cost, other times with a profit compared to last week's purchase price. In addition, Novo Nordisk provides ordinary dividend twice a year at the present time, in addition to the possible gain on the price by buying and selling on a weekly basis. And in the long term, the potential is greater And I'm happy to wait
- ·20 t sittenis not worth the risk for me, glad that I didn't buy in.
- ·22 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.I generally agree, but also think the case is more uncertain than it was in 2024. CagriSema has disappointed relative to expectations, and Novo must now prove that zenagamtide and the rest of the pipeline can actually take over as the next growth engine. The market is growing, but that doesn't mean Novo automatically will. That's exactly what CMD needs to convince investors of.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt